moxonidine

Moxonidine is a centrally acting antihypertensive drug classified as an imidazoline/alpha-2 receptor agonist. It is primarily used for the treatment of mild to moderate essential hypertension, especially in patients who do not respond adequately to or cannot tolerate other antihypertensive agents such as ACE inhibitors, beta-blockers, calcium channel blockers, or thiazide diuretics[1][4][5]. Moxonidine acts mainly by selectively stimulating imidazoline I1 receptors in the rostral ventrolateral medulla of the brainstem and has much less activity at central alpha-2 adrenoceptors compared to older drugs like clonidine[1][2][3]. This action reduces sympathetic nervous system outflow and lowers systemic vascular resistance and arterial blood pressure[1][6]. Additional benefits include potential improvements in insulin resistance and glucose tolerance as well as protective effects against hypertensive organ damage such as left ventricular hypertrophy and kidney disease[2][3][5].

Brand names

PhysiotensMoxonCyntMoxonidine GH

Other names

4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine